The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study to investigate the
safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in
subjects with symptomatic cerebral cavernous malformation (CCM).